Celine H M Leenen1, Anne Goverde1,2, Esther W de Bekker-Grob3, Anja Wagner2, Margot G F van Lier1, Manon C W Spaander1, Marco J Bruno1, Carli M Tops4, Ans M W van den Ouweland2, Hendrikus J Dubbink5, Ernst J Kuipers1,6, Winand N M Dinjens5, Monique E van Leerdam1,7, Ewout W Steyerberg3. 1. Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands. 2. Department of Clinical Genetics, Erasmus MC, University Medical Center, Rotterdam, The Netherlands. 3. Department of Public Health, Erasmus MC, University Medical Center, Rotterdam, The Netherlands. 4. Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands. 5. Department of Pathology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands. 6. Department of Internal Medicine, Erasmus MC, University Medical Center, Rotterdam, The Netherlands. 7. Current address: Department of Gastroenterology and Hepatology, Antoni van Leeuwenhoek Hospital, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Abstract
PURPOSE: To assess the cost-effectiveness of routine Lynch syndrome (LS) screening among colorectal cancer (CRC) patients ≤70 years of age. METHODS: A population-based series of CRC patients ≤70 years of age was routinely screened for LS. We calculated life years gained (LYG) and incremental cost-effectiveness ratios (ICERs) for different age cutoffs and comparing age-targeted screening with the revised Bethesda guidelines. RESULTS: Screening 1,117 CRC patients identified 23 LS patients, of whom 7 were ≤50 years of age, 7 were 51-60, and 9 were 61-70. Additionally, 70 LS carriers were identified among relatives (14, 42, and 14 per age category). Screening amounted to 205.9 LYG or 43.6, 118.0, and 44.3 LYG per age category. ICERs were [euro ]4.226/LYG for screening CRC patients ≤60 years of age compared with those ≤50 years and [euro ]7.051/LYG for screening CRC patients ≤70 years compared with those ≤60 years. The revised Bethesda guidelines identified 70 of 93 (75%) LS carriers. The ICER for LS screening in CRC patients ≤70 years of age compared with the revised Bethesda guidelines was [euro ]7.341/LYG. All ICERs remained less than [euro ]13.000/LYG in one-way sensitivity analyses. CONCLUSION: Routine LS screening by analysis of microsatellite instability, immunohistochemistry, and MLH1 hypermethylation in CRC patients ≤70 years of age is a cost-effective strategy with important clinical benefits for CRC patients and their relatives.Genet Med 18 10, 966-973.
PURPOSE: To assess the cost-effectiveness of routine Lynch syndrome (LS) screening among colorectal cancer (CRC) patients ≤70 years of age. METHODS: A population-based series of CRC patients ≤70 years of age was routinely screened for LS. We calculated life years gained (LYG) and incremental cost-effectiveness ratios (ICERs) for different age cutoffs and comparing age-targeted screening with the revised Bethesda guidelines. RESULTS: Screening 1,117 CRC patients identified 23 LS patients, of whom 7 were ≤50 years of age, 7 were 51-60, and 9 were 61-70. Additionally, 70 LS carriers were identified among relatives (14, 42, and 14 per age category). Screening amounted to 205.9 LYG or 43.6, 118.0, and 44.3 LYG per age category. ICERs were [euro ]4.226/LYG for screening CRC patients ≤60 years of age compared with those ≤50 years and [euro ]7.051/LYG for screening CRC patients ≤70 years compared with those ≤60 years. The revised Bethesda guidelines identified 70 of 93 (75%) LS carriers. The ICER for LS screening in CRC patients ≤70 years of age compared with the revised Bethesda guidelines was [euro ]7.341/LYG. All ICERs remained less than [euro ]13.000/LYG in one-way sensitivity analyses. CONCLUSION: Routine LS screening by analysis of microsatellite instability, immunohistochemistry, and MLH1 hypermethylation in CRC patients ≤70 years of age is a cost-effective strategy with important clinical benefits for CRC patients and their relatives.Genet Med 18 10, 966-973.
Authors: Margot G F van Lier; Celine H M Leenen; Anja Wagner; Dewkoemar Ramsoekh; Hendrikus J Dubbink; Ans M W van den Ouweland; Pieter J Westenend; Eelco J R de Graaf; Leonieke M M Wolters; Wietske W Vrijland; Ernst J Kuipers; Monique E van Leerdam; Ewout W Steyerberg; Winand N M Dinjens Journal: J Pathol Date: 2012-01-17 Impact factor: 7.996
Authors: C Lamberti; E Mangold; C Pagenstecher; M Jungck; D Schwering; M Bollmann; J Vogel; D Kindermann; R Nikorowitsch; N Friedrichs; B Schneider; F Houshdaran; I G H Schmidt-Wolf; W Friedl; P Propping; T Sauerbruch; R Büttner; M Mathiak Journal: Digestion Date: 2006-03-03 Impact factor: 3.216
Authors: Scott Ramsey; David Blough; Cara McDermott; Lauren Clarke; Robin Bennett; Wylie Burke; Polly Newcomb Journal: Public Health Genomics Date: 2009-03-02 Impact factor: 2.000
Authors: Franziska Severin; Björn Stollenwerk; Elke Holinski-Feder; Elisabeth Meyer; Volker Heinemann; Clemens Giessen-Jung; Wolf Rogowski Journal: Genet Med Date: 2015-01-08 Impact factor: 8.822
Authors: Deanna S Cross; Alanna Kulchak Rahm; Tia L Kauffman; Jennifer Webster; Anh Quynh Le; Heather Spencer Feigelson; Gwen Alexander; Paul Meier; Adedayo A Onitilo; Pamala A Pawloski; Andrew E Williams; Stacey Honda; Yeehwa Daida; Catherine A McCarty; Katrina A B Goddard Journal: Genet Med Date: 2013-05-02 Impact factor: 8.822
Authors: C Guillén-Ponce; E Lastra; I Lorenzo-Lorenzo; T Martín Gómez; R Morales Chamorro; A B Sánchez-Heras; R Serrano; M C Soriano Rodríguez; J L Soto; L Robles Journal: Clin Transl Oncol Date: 2020-01-24 Impact factor: 3.405
Authors: Karl Johnson; Katherine W Saylor; Isabella Guynn; Karen Hicklin; Jonathan S Berg; Kristen Hassmiller Lich Journal: Genet Med Date: 2021-12-07 Impact factor: 8.822
Authors: K T S Aiyer; T Doeleman; N A Ryan; M Nielsen; E J Crosbie; V T H B M Smit; H Morreau; J J Goeman; T Bosse Journal: Mod Pathol Date: 2022-09-14 Impact factor: 8.209
Authors: Daniel Novinson; Mary Puckett; Julie Townsend; Guillermo Tortolero-Luna; Jenny Rees Patterson; Cynthia A Gelb; Sherri L Stewart Journal: J Cancer Educ Date: 2019-12 Impact factor: 2.037
Authors: Elisabeth F P Peterse; Steffie K Naber; Corinne Daly; Aaron Pollett; Lawrence F Paszat; Manon C W Spaander; Melyssa Aronson; Robert Gryfe; Linda Rabeneck; Iris Lansdorp-Vogelaar; Nancy N Baxter Journal: Clin Gastroenterol Hepatol Date: 2019-10-17 Impact factor: 11.382